Related references
Note: Only part of the references are listed.Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia
Kiran Naqvi et al.
CANCER (2020)
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy
Fabio Efficace et al.
LEUKEMIA (2020)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2020)
Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212
Itaru Matsumura et al.
BLOOD (2020)
Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
Valentin Garcia-Gutierrez et al.
FRONTIERS IN ONCOLOGY (2019)
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients
Mario Tiribelli et al.
Oncotarget (2018)
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis
Francis J. Giles et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Andreas Hochhaus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Analyses of Treatment Outcome According to Age in Patients With Chronic Myeloid Leukemia Receiving Front-line Imatinib Therapy
Irena Cojbasic et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials
Matteo Molica et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034
Neil P. Shah et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Hannah Bower et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib - a retrospective chart review analysis
James D. Griffin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
F. J. Giles et al.
LEUKEMIA (2013)
Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: A systematic review of efficacy and safety data
Massimo Breccia et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation
G. Rogers et al.
HEALTH TECHNOLOGY ASSESSMENT (2012)
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Hagop M. Kantarjian et al.
BLOOD (2011)
Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis
Hugues de Lavallade et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials
C. M. Lucas et al.
LEUKEMIA (2008)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Share Paper
